Search for "manganese" in Full Text gives 91 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2014, 10, 641–652, doi:10.3762/bjoc.10.56
Graphical Abstract
Figure 1: Raspberry Pi® (RPi) computer operating in the laboratory, shown here without its protective case. U...
Figure 2: Two step approach to piperazine-2-carboxamide via hydrolysis followed by reduction. (a) Retrosynthe...
Figure 3: Heterogeneous hydration of pyrazine-2-carbonitrile with hydrous zirconia.
Figure 4: FlowIR™ profile for the reactor output after hydration of pyrazine-2-carbonitrile using hydrous zir...
Figure 5: (a) Fluidic setup for the zirconia catalysed hydration of aromatic nitrile. (b) Raspberry Pi® micro...
Figure 6: Flowchart describing the control sequence for operating and monitoring the hydration reaction. The ...
Figure 7: Profile for a 3 hour reaction simulating a long run. The absorbance shown is that at 1685 cm−1, whi...
Figure 8: Reactor setup for optimisation reactions. A multi-position valve (V2) was used for collecting sampl...
Figure 9: Representation of the control sequence for running experiments under a set of conditions. (See Supporting Information File 3 for...
Figure 10: Reduction products of piperazine-2-carboxamide.
Figure 11: (a) In-line reservoir schematic. The liquid level is measured by observation of a plastic float. (b...
Figure 12: Flow set up for the automated machine assisted synthesis of (R,S)-piperidine-2-carboxamide.
Figure 13: Control sequence for the two-step process.
Figure 14: Chart of monitored parameters over a 15 hour reaction. The output from the hydrolysis step is direc...
Beilstein J. Org. Chem. 2014, 10, 425–431, doi:10.3762/bjoc.10.39
Beilstein J. Org. Chem. 2014, 10, 34–114, doi:10.3762/bjoc.10.6
Graphical Abstract
Figure 1: Five and six-membered cyclic peroxides.
Figure 2: Artemisinin and semi-synthetic derivatives.
Scheme 1: Synthesis of 3-hydroxy-1,2-dioxolanes 3a–c.
Scheme 2: Synthesis of dioxolane 6.
Scheme 3: Photooxygenation of oxazolidines 7a–d with formation of spiro-fused oxazolidine-containing dioxolan...
Scheme 4: Oxidation of cyclopropanes 10a–e and 11a–e with preparation of 1,2-dioxolanes 12a–e.
Scheme 5: VO(acac)2-catalyzed oxidation of silylated bicycloalkanols 13a–c.
Scheme 6: Mn(II)-catalyzed oxidation of cyclopropanols 15a–g.
Scheme 7: Oxidation of aminocyclopropanes 20a–c.
Scheme 8: Synthesis of aminodioxolanes 24.
Figure 3: Trifluoromethyl-containing dioxolane 25.
Scheme 9: Synthesis of 1,2-dioxolanes 27a–e by the oxidation of cyclopropanes 26a–e.
Scheme 10: Photoinduced oxidation of methylenecyclopropanes 28.
Scheme 11: Irradiation-mediated oxidation.
Scheme 12: Application of diazene 34 for dioxolane synthesis.
Scheme 13: Mn(OAc)3-catalyzed cooxidation of arylacetylenes 37a–h and acetylacetone with atmospheric oxygen.
Scheme 14: Peroxidation of (2-vinylcyclopropyl)benzene (40).
Scheme 15: Peroxidation of 1,4-dienes 43a,b.
Scheme 16: Peroxidation of 1,5-dienes 46.
Scheme 17: Peroxidation of oxetanes 53a,b.
Scheme 18: Peroxidation of 1,6-diene 56.
Scheme 19: Synthesis of 3-alkoxy-1,2-dioxolanes 62a,b.
Scheme 20: Synthesis of spiro-bis(1,2-dioxolane) 66.
Scheme 21: Synthesis of dispiro-1,2-dioxolanes 68, 70, 71.
Scheme 22: Synthesis of spirohydroperoxydioxolanes 75a,b.
Scheme 23: Synthesis of spirohydroperoxydioxolane 77 and dihydroperoxydioxolane 79.
Scheme 24: Ozonolysis of azepino[4,5-b]indole 80.
Scheme 25: SnCl4-mediated fragmentation of ozonides 84a–l in the presence of allyltrimethylsilane.
Scheme 26: SnCl4-mediated fragmentation of bicyclic ozonide 84m in the presence of allyltrimethylsilane.
Scheme 27: MCl4-mediated fragmentation of alkoxyhydroperoxides 96 in the presence of allyltrimethylsilane.
Scheme 28: SnCl4-catalyzed reaction of monotriethylsilylperoxyacetal 108 with alkene 109.
Scheme 29: SnCl4-catalyzed reaction of triethylsilylperoxyacetals 111 with alkenes.
Scheme 30: Desilylation of tert-butyldimethylsilylperoxy ketones 131a,b followed by cyclization.
Scheme 31: Deprotection of peroxide 133 followed by cyclization.
Scheme 32: Asymmetric peroxidation of methyl vinyl ketones 137a–e.
Scheme 33: Et2NH-catalyzed intramolecular cyclization.
Scheme 34: Synthesis of oxodioxolanes 143a–j.
Scheme 35: Haloperoxidation accompanied by intramolecular ring closure.
Scheme 36: Oxidation of triterpenes 149a–d with Na2Cr2O7/N-hydroxysuccinimide.
Scheme 37: Curtius and Wolff rearrangements to form 1,2-dioxolane ring-retaining products.
Scheme 38: Oxidative desilylation of peroxide 124.
Scheme 39: Synthesis of dioxolane 158, a compound containing the aminoquinoline antimalarial pharmacophore.
Scheme 40: Diastereomers of plakinic acid A, 162a and 162b.
Scheme 41: Ozonolysis of alkenes.
Scheme 42: Cross-ozonolysis of alkenes 166 with carbonyl compounds.
Scheme 43: Ozonolysis of the bicyclic cyclohexenone 168.
Scheme 44: Cross-ozonolysis of enol ethers 172a,b with cyclohexanone.
Scheme 45: Griesbaum co-ozonolysis.
Scheme 46: Reactions of aryloxiranes 177a,b with oxygen.
Scheme 47: Intramolecular formation of 1,2,4-trioxolane 180.
Scheme 48: Formation of 1,2,4-trioxolane 180 by the reaction of 1,5-ketoacetal 181 with H2O2.
Scheme 49: 1,2,4-Trioxolane 186 with tetrazole fragment.
Scheme 50: 1,2,4-Trioxolane 188 with a pyridine fragment.
Scheme 51: 1,2,4-Trioxolane 189 with pyrimidine fragment.
Scheme 52: Synthesis of aminoquinoline-containing 1,2,4-trioxalane 191.
Scheme 53: Synthesis of arterolane.
Scheme 54: Oxidation of diarylheptadienes 197a–c with singlet oxygen.
Scheme 55: Synthesis of hexacyclinol peroxide 200.
Scheme 56: Oxidation of enone 201 and enenitrile 203 with singlet oxygen.
Scheme 57: Synthesis of 1,2-dioxanes 207 by oxidative coupling of carbonyl compounds 206 and alkenes 205.
Scheme 58: 1,2-Dioxanes 209 synthesis by co-oxidation of 1,5-dienes 208 and thiols.
Scheme 59: Synthesis of bicyclic 1,2-dioxanes 212 with aryl substituents.
Scheme 60: Isayama–Mukaiyama peroxysilylation of 1,5-dienes 213 followed by desilylation under acidic conditio...
Scheme 61: Synthesis of bicycle 218 with an 1,2-dioxane ring.
Scheme 62: Intramolecular cyclization with an oxirane-ring opening.
Scheme 63: Inramolecular cyclization with the oxetane-ring opening.
Scheme 64: Intramolecular cyclization with the attack on a keto group.
Scheme 65: Peroxidation of the carbonyl group in unsaturated ketones 228 followed by cyclization of hydroperox...
Scheme 66: CsOH and Et2NH-catalyzed cyclization.
Scheme 67: Preparation of peroxyplakoric acid methyl ethers A and D.
Scheme 68: Hg(OAc)2 in 1,2-dioxane synthesis.
Scheme 69: Reaction of 1,4-diketones 242 with hydrogen peroxide.
Scheme 70: Inramolecular cyclization with oxetane-ring opening.
Scheme 71: Inramolecular cyclization with MsO fragment substitution.
Scheme 72: Synthesis of 1,2-dioxane 255a, a structurally similar compound to natural peroxyplakoric acids.
Scheme 73: Synthesis of 1,2-dioxanes based on the intramolecular cyclization of hydroperoxides containing C=C ...
Scheme 74: Use of BCIH in the intramolecular cyclization.
Scheme 75: Palladium-catalyzed cyclization of δ-unsaturated hydroperoxides 271a–e.
Scheme 76: Intramolecular cyclization of unsaturated peroxyacetals 273a–d.
Scheme 77: Allyltrimethylsilane in the synthesis of 1,2-dioxanes 276a–d.
Scheme 78: Intramolecular cyclization using the electrophilic center of the peroxycarbenium ion 279.
Scheme 79: Synthesis of bicyclic 1,2-dioxanes.
Scheme 80: Preparation of 1,2-dioxane 286.
Scheme 81: Di(tert-butyl)peroxalate-initiated radical cyclization of unsaturated hydroperoxide 287.
Scheme 82: Oxidation of 1,4-betaines 291a–d.
Scheme 83: Synthesis of aminoquinoline-containing 1,2-dioxane 294.
Scheme 84: Synthesis of the sulfonyl-containing 1,2-dioxane.
Scheme 85: Synthesis of the amido-containing 1,2-dioxane 301.
Scheme 86: Reaction of singlet oxygen with the 1,3-diene system 302.
Scheme 87: Synthesis of (+)-premnalane А and 8-epi-premnalane A.
Scheme 88: Synthesis of the diazo group containing 1,2-dioxenes 309a–e.
Figure 4: Plakortolide Е.
Scheme 89: Synthesis of 6-epiplakortolide Е.
Scheme 90: Application of Bu3SnH for the preparation of tetrahydrofuran-containing bicyclic peroxides 318a,b.
Scheme 91: Application of Bu3SnH for the preparation of lactone-containing bicyclic peroxides 320a–f.
Scheme 92: Dihydroxylation of the double bond in the 1,2-dioxene ring 321 with OsO4.
Scheme 93: Epoxidation of 1,2-dioxenes 324.
Scheme 94: Cyclopropanation of the double bond in endoperoxides 327.
Scheme 95: Preparation of pyridazine-containing bicyclic endoperoxides 334a–c.
Scheme 96: Synthesis of 1,2,4-trioxanes 337 by the hydroperoxidation of unsaturated alcohols 335 with 1O2 and ...
Scheme 97: Synthesis of sulfur-containing 1,2,4-trioxanes 339.
Scheme 98: BF3·Et2O-catalyzed synthesis of the 1,2,4-trioxanes 342a–g.
Scheme 99: Photooxidation of enol ethers or vinyl sulfides 343.
Scheme 100: Synthesis of tricyclic peroxide 346.
Scheme 101: Reaction of endoperoxides 348a,b derived from cyclohexadienes 347a,b with 1,4-cyclohexanedione.
Scheme 102: [4 + 2]-Cycloaddition of singlet oxygen to 2Н-pyrans 350.
Scheme 103: Synthesis of 1,2,4-trioxanes 354 using peroxysilylation stage.
Scheme 104: Epoxide-ring opening in 355 with H2O2 followed by the condensation of hydroxy hydroperoxides 356 wi...
Scheme 105: Peroxidation of unsaturated ketones 358 with the H2O2/CF3COOH/H2SO4 system.
Scheme 106: Synthesis of 1,2,4-trioxanes 362 through Et2NH-catalyzed intramolecular cyclization.
Scheme 107: Reduction of the double bond in tricyclic peroxides 363.
Scheme 108: Horner–Wadsworth–Emmons reaction in the presence of peroxide group.
Scheme 109: Reduction of ester group by LiBH4 in the presence of 1,2,4-trioxane moiety.
Scheme 110: Reductive amination of keto-containing 1,2,4-trioxane 370.
Scheme 111: Reductive amination of keto-containing 1,2,4-trioxane and a Fe-containing moiety.
Scheme 112: Acid-catalyzed reactions of Н2О2 with ketones and aldehydes 374.
Scheme 113: Cyclocondensation of carbonyl compounds 376a–d using Me3SiOOSiMe3/CF3SO3SiMe3.
Scheme 114: Peroxidation of 4-methylcyclohexanone (378).
Scheme 115: Synthesis of symmetrical tetraoxanes 382a,b from aldehydes 381a,b.
Scheme 116: Synthesis of unsymmetrical tetraoxanes using of MeReO3.
Scheme 117: Synthesis of symmetrical tetraoxanes using of MeReO3.
Scheme 118: Synthesis of symmetrical tetraoxanes using of MeReO3.
Scheme 119: MeReO3 in the synthesis of symmetrical tetraoxanes with the use of aldehydes.
Scheme 120: Preparation of unsymmmetrical 1,2,4,5-tetraoxanes with high antimalarial activity.
Scheme 121: Re2O7-Catalyzed synthesis of tetraoxanes 398.
Scheme 122: H2SO4-Catalyzed synthesis of steroidal tetraoxanes 401.
Scheme 123: HBF4-Catalyzed condensation of bishydroperoxide 402 with 1,4-cyclohexanedione.
Scheme 124: BF3·Et2O-Catalyzed reaction of gem-bishydroperoxides 404 with enol ethers 405 and acetals 406.
Scheme 125: HBF4-Catalyzed cyclocondensation of bishydroperoxide 410 with ketones.
Scheme 126: Synthesis of symmetrical and unsymmetrical tetraoxanes 413 from benzaldehydes 412.
Scheme 127: Synthesis of bridged 1,2,4,5-tetraoxanes 415a–l from β-diketones 414a–l and H2O2.
Scheme 128: Dimerization of zwitterions 417.
Scheme 129: Ozonolysis of verbenone 419.
Scheme 130: Ozonolysis of O-methyl oxime 424.
Scheme 131: Peroxidation of 1,1,1-trifluorododecan-2-one 426 with oxone.
Scheme 132: Intramolecular cyclization of dialdehyde 428 with H2O2.
Scheme 133: Tetraoxanes 433–435 as by-products in peroxidation of ketals 430–432.
Scheme 134: Transformation of triperoxide 436 in diperoxide 437.
Scheme 135: Preparation and structural modifications of tetraoxanes.
Scheme 136: Structural modifications of steroidal tetraoxanes.
Scheme 137: Synthesis of 1,2,4,5-tetraoxane 454 containing the fluorescent moiety.
Scheme 138: Synthesis of tetraoxane 458 (RKA182).
Beilstein J. Org. Chem. 2013, 9, 2434–2445, doi:10.3762/bjoc.9.281
Graphical Abstract
Scheme 1: Synthesis of D-tagatose from D-galactose using L-arabinose isomerase.
Scheme 2: Synthesis of D-psicose from D-fructose using D-tagatose 3-epimerase/D-psicose 3-epimerase.
Figure 1: The active site in D-psicose 3-epimerase (DPEase) in the presence of D-fructose, showing the metal ...
Scheme 3: Enzymatic synthesis of D-psicose using aldolase FucA.
Scheme 4: Proposed pathway of the D-sorbose synthesis from galactitol or L-glucitol.
Scheme 5: Simultaneous enzymatic synthesis of D-sorbose and D-psicose.
Scheme 6: Biosynthesis of L-tagatose.
Scheme 7: Preparative-scale synthesis of L-tagatose and L-fructose using aldolase.
Scheme 8: Biosynthesis of L-fructose.
Scheme 9: Preparative-scale synthesis of L-fructose using aldolase RhaD.
Scheme 10: Chemoenzymatically synthesis of 1-deoxy-L-fructose [8].
Scheme 11: Potential enzymes (isomerases) for the bioconversion of D-psicose to D-allose.
Scheme 12: Three-step bioconversion of D-glucose to D-allose.
Scheme 13: Biosynthesis of L-glucose.
Scheme 14: Enzymatic synthesis of L-talose and D-gulose.
Scheme 15: Enzymatic synthesis of L-galactose.
Scheme 16: Enzymatic synthesis of L-fucose.
Scheme 17: Synthesis of allitol from D-fructose using a multi-enzyme system.
Scheme 18: Biosynthesis of D-talitol via C-2 reduction of rare sugars.
Scheme 19: Biosynthesis of L-sorbitol via C-2 reduction of rare sugars.
Beilstein J. Org. Chem. 2013, 9, 2265–2319, doi:10.3762/bjoc.9.265
Graphical Abstract
Scheme 1: Scaled industrial processes for the synthesis of simple pyridines.
Scheme 2: Synthesis of nicotinic acid from 2-methyl-5-ethylpyridine (1.11).
Scheme 3: Synthesis of 3-picoline and nicotinic acid.
Scheme 4: Synthesis of 3-picoline from 2-methylglutarodinitrile 1.19.
Scheme 5: Picoline-based synthesis of clarinex (no yields reported).
Scheme 6: Mode of action of proton-pump inhibitors and structures of the API’s.
Scheme 7: Hantzsch-like route towards the pyridine rings in common proton pump inhibitors.
Figure 1: Structures of rosiglitazone (1.40) and pioglitazone (1.41).
Scheme 8: Synthesis of rosiglitazone.
Scheme 9: Syntheses of 2-pyridones.
Scheme 10: Synthesis and mechanism of 2-pyrone from malic acid.
Scheme 11: Polymer-assisted synthesis of rosiglitazone.
Scheme 12: Synthesis of pioglitazone.
Scheme 13: Meerwein arylation reaction towards pioglitazone.
Scheme 14: Route towards pioglitazone utilising tyrosine.
Scheme 15: Route towards pioglitazone via Darzens ester formation.
Scheme 16: Syntheses of the thiazolidinedione moiety.
Scheme 17: Synthesis of etoricoxib utilising Negishi and Stille cross-coupling reactions.
Scheme 18: Synthesis of etoricoxib via vinamidinium condensation.
Figure 2: Structures of nalidixic acid, levofloxacin and moxifloxacin.
Scheme 19: Synthesis of moxifloxacin.
Scheme 20: Synthesis of (S,S)-2,8-diazabicyclo[4.3.0]nonane 1.105.
Scheme 21: Synthesis of levofloxacin.
Scheme 22: Alternative approach to the levofloxacin core 1.125.
Figure 3: Structures of nifedipine, amlodipine and clevidipine.
Scheme 23: Mg3N2-mediated synthesis of nifedipine.
Scheme 24: Synthesis of rac-amlodipine as besylate salt.
Scheme 25: Aza Diels–Alder approach towards amlodipine.
Scheme 26: Routes towards clevidipine.
Figure 4: Examples of piperidine containing drugs.
Figure 5: Discovery of tiagabine based on early leads.
Scheme 27: Synthetic sequences to tiagabine.
Figure 6: Structures of solifenacin (2.57) and muscarine (2.58).
Scheme 28: Enantioselective synthesis of solifenacin.
Figure 7: Structures of DPP-4 inhibitors of the gliptin-type.
Scheme 29: Formation of inactive diketopiperazines from cis-rotameric precursors.
Figure 8: Co-crystal structure of carmegliptin bound in the human DPP-4 active site (PDB 3kwf).
Scheme 30: Improved route to carmegliptin.
Figure 9: Structures of lamivudine and zidovudine.
Scheme 31: Typical routes accessing uracil, thymine and cytosine.
Scheme 32: Coupling between pyrimidones and riboses via the Vorbrüggen nucleosidation.
Scheme 33: Synthesis of lamivudine.
Scheme 34: Synthesis of raltegravir.
Scheme 35: Mechanistic studies on the formation of 3.22.
Figure 10: Structures of selected pyrimidine containing drugs.
Scheme 36: General preparation of pyrimidines and dihydropyrimidones.
Scheme 37: Synthesis of imatinib.
Scheme 38: Flow synthesis of imatinib.
Scheme 39: Syntheses of erlotinib.
Scheme 40: Synthesis of erlotinib proceeding via Dimroth rearrangement.
Scheme 41: Synthesis of lapatinib.
Scheme 42: Synthesis of rosuvastatin.
Scheme 43: Alternative preparation of the key aldehyde towards rosuvastatin.
Figure 11: Structure comparison between nicotinic acetylcholine receptor agonists.
Scheme 44: Syntheses of varenicline and its key building block 4.5.
Scheme 45: Synthetic access to eszopiclone and brimonidine via quinoxaline intermediates.
Figure 12: Bortezomib bound in an active site of the yeast 20S proteasome ([114], pdb 2F16).
Scheme 46: Asymmetric synthesis of bortezomib.
Figure 13: Structures of some prominent piperazine containing drugs.
Figure 14: Structural comparison between the core of aplaviroc (4.35) and a type-1 β-turn (4.36).
Scheme 47: Examplary synthesis of an aplaviroc analogue via the Ugi-MCR.
Scheme 48: Syntheses of azelastine (5.1).
Figure 15: Structures of captopril, enalapril and cilazapril.
Scheme 49: Synthesis of cilazapril.
Figure 16: Structures of lamotrigine, ceftriaxone and azapropazone.
Scheme 50: Synthesis of lamotrigine.
Scheme 51: Alternative synthesis of lamotrigine (no yields reported).
Figure 17: Structural comparison between imiquimod and the related adenosine nucleoside.
Scheme 52: Conventional synthesis of imiquimod (no yields reported).
Scheme 53: Synthesis of imiquimod.
Scheme 54: Synthesis of imiquimod via tetrazole formation (not all yields reported).
Figure 18: Structures of various anti HIV-medications.
Scheme 55: Synthesis of abacavir.
Figure 19: Structures of diazepam compared to modern replacements.
Scheme 56: Synthesis of ocinaplon.
Scheme 57: Access to zaleplon and indiplon.
Scheme 58: Different routes towards the required N-methylpyrazole 6.65 of sildenafil.
Scheme 59: Polymer-supported reagents in the synthesis of key aminopyrazole 6.72.
Scheme 60: Early synthetic route to sildenafil.
Scheme 61: Convergent preparations of sildenafil.
Figure 20: Comparison of the structures of sildenafil, tadalafil and vardenafil.
Scheme 62: Short route to imidazotriazinones.
Scheme 63: Alternative route towards vardenafils core imidazotriazinone (6.95).
Scheme 64: Bayer’s approach to the vardenafil core.
Scheme 65: Large scale synthesis of vardenafil.
Scheme 66: Mode of action of temozolomide (6.105) as methylating agent.
Scheme 67: Different routes to temozolomide.
Scheme 68: Safer route towards temozolomide.
Figure 21: Some unreported heterocyclic scaffolds in top market drugs.
Beilstein J. Org. Chem. 2013, 9, 1437–1442, doi:10.3762/bjoc.9.162
Graphical Abstract
Figure 1: Flow setup for alcohol oxidations.
Scheme 1: Oxidation–condensation sequence in the synthesis of 2,3-dimethylquinoxaline.
Beilstein J. Org. Chem. 2013, 9, 710–716, doi:10.3762/bjoc.9.81
Graphical Abstract
Scheme 1: Synthesis of substrates 1a–c.
Scheme 2: Synthesis of substrates 5a, 5c, 6a and 6c.
Scheme 3: Cyclization of substrate 5a and 5c.
Scheme 4: Proposed mechanism involving π-allylnickel formation.
Scheme 5: Cyclization of substrate 6a and 6c.
Scheme 6: Synthesis and carbometalations of 13.
Beilstein J. Org. Chem. 2013, 9, 557–576, doi:10.3762/bjoc.9.61
Graphical Abstract
Scheme 1: Key radical step in the total synthesis of (–)-dendrobine.
Scheme 2: Radical cascade in the total synthesis of (±)-13-deoxyserratine (ACCN = 1,1'-azobis(cyclohexanecarb...
Scheme 3: Formation of the complete skeleton of (±)-fortucine.
Scheme 4: Model radical sequence for the synthesis of quadrone.
Scheme 5: Radical cascade using the Barton decarboxylation.
Scheme 6: Simplified mechanism for the xanthate addition to alkenes.
Scheme 7: Synthesis of β-lactam derivatives.
Scheme 8: Sequential additions to three different alkenes (PhthN = phthalimido).
Scheme 9: Key cascade in the total synthesis of (±)-matrine (43).
Scheme 10: Synthesis of complex tetralones.
Scheme 11: Synthesis of functionalised azaindoline and indole derivatives.
Scheme 12: Synthesis of thiochromanones.
Scheme 13: Synthesis of complex benzothiepinones. Conditions: 1) CF3COOH; 2) RCHO / AcOH (PMB = p-methoxybenzy...
Scheme 14: Formation and capture of a cyclic nitrone.
Scheme 15: Synthesis of bicyclic cyclobutane motifs.
Scheme 16: Construction of the CD rings of steroids.
Scheme 17: Rapid assembly of polyquinanes.
Scheme 18: Formation of a polycyclic structure via an allene intermediate.
Scheme 19: A polycyclic structure via the alkylative Birch reduction.
Scheme 20: Synthesis of polycyclic pyrimidines and indoline structures.
Scheme 21: Construction of a trans-decalin derivative.
Scheme 22: Multiple uses of a chloroacetonyl xanthate.
Scheme 23: A convergent route to spiroketals.
Scheme 24: A modular approach to 3-arylpiperidines.
Scheme 25: A convergent route to cyclopentanols and to functional allenes.
Scheme 26: Allylation and vinylation of a xanthate and an iodide.
Scheme 27: Vinyl epoxides as allylating agents.
Scheme 28: Radical allylations using allylic alcohol derivatives.
Scheme 29: Synthesis of variously substituted lactams.
Scheme 30: Nickel-mediated synthesis of unsaturated lactams.
Scheme 31: Total synthesis of (±)-3-demethoxy-erythratidinone.
Scheme 32: Generation and capture of an iminyl radical from an oxime ester.
Beilstein J. Org. Chem. 2013, 9, 342–391, doi:10.3762/bjoc.9.39
Graphical Abstract
Figure 1: Change of electron distribution between HS and LS states of an octahedral iron(II) coordination com...
Figure 2: Types of spin transition curves in terms of the molar fraction of HS molecules, γHS(T), as a functi...
Figure 3: Single crystal UV–vis spectra of the spin crossover compound [Fe(ptz)6](BF4)2 (ptz = 1-propyltetraz...
Figure 4: Thermal spin crossover in [Fe(ptz)6](BF4)2 (ptz = 1-propyltetrazole) recorded at three different te...
Figure 5: (a) Mössbauer spectra of the LS compound [Fe(phen)3]X2 recorded over the temperature range 300–5 K....
Figure 6: (left) Demonstration of light-induced spin state trapping (LIESST) in [Fe(ptz)6]BF4)2 with 57Fe Mös...
Figure 7: Schematic representation of the pressure influence (p2 > p1) on the LS and HS potential wells of an...
Figure 8: χMT versus T curves at different pressures for [Fe(phen)2(NCS)2], polymorph II. (Reproduced with pe...
Figure 9: Molecular structure (a) and γHS(T) curves at different pressures for [CrI2(depe)2] (b) (Reproduced ...
Figure 10: HS molar fraction γHS versusT at different pressures for [Fe(phy)2](BF4)2. The hysteresis loop broa...
Figure 11: Proposed structure of the polymeric [Fe(4R-1,2,4-triazole)3]2+ spin crossover cation (a) and plot o...
Figure 12: Temperature dependence of the HS fraction γHS(T), determined from Mössbauer spectra of [Fe(II)xZn1-x...
Figure 13: Influence of the noncoordinated anion on the spin transition curve γHS(T) near the transition tempe...
Figure 14: Spin transition curves γHS(T) for different solvates of the SCO complexes. [Fe(II)(2-pic)3]Cl2·Solv...
Figure 15: ST curves γHS(T) of the deuterated solvates of [Fe(II)(2-pic)3]Cl2·Solv with Solv = C2D5OH and C2H5...
Figure 16: Sketch of the two-step spin transition; [LS–LS] pair is diamagnetic, [LS–HS] is paramagnetic and th...
Figure 17: (left) Temperature dependence of χMT for {[Fe(L)(NCX)2]2bpym}(L = bpym or bt and X = S or Se). (rig...
Figure 18: Temperature dependence of χMT for [bpym, NCS−] (left) and [bpym, NCSe−] (right) at different pressu...
Figure 19: 57Fe Mössbauer spectra of [bpym, NCSe−] measured at 4.2 K at zero field (a) and at 5 T (b) (see tex...
Figure 20: Temperature dependence of χMT for [Fe2(L)3](ClO4)4·2H2O showing a complete two-step spin conversion...
Figure 21: (a) View of the dinuclear unit in the crystal structure of [Fe2(Hsaltrz)5(NCS)4]·4MeOH. (b) Tempera...
Figure 22: (left) AFM pattern recorded in tapping mode at room temperature on hexagonal single crystals of [Fe3...
Figure 23: (right) Stepwise SCO in an Fe4 [2 × 2] grid, which reveals a smooth magnetic profile under ambient ...
Figure 24: (left) View of the discrete nanoball made of Fe(II) SCO units as well as Cu(I) building blocks. (ri...
Figure 25:
(left) Linear dependency between T1/2 in the heating (Δ) and cooling () modes versus the anion volu...
Figure 26: (left) View of the linear chain structure of [Fe(1,2-bis(tetrazol-1-yl)propane)3]2+ along the a axi...
Figure 27: (left) View of the 2D layered structure of [Fe(btr)2(NCS)2]·H2O (at 293 K). The water molecules (in...
Figure 28: (left) Three interpenetrated square networks for [Fe(bpb)2(NCS)2]·MeOH. (right) χMT versus T plot s...
Figure 29: Part of the crystal structure of [Fe{N(entz)3}](BF4)2 (T = 293 K) [335,336]. (Reproduced with permission fro...
Figure 30: (left) Projection of the crystal structure of [Fe(btr)3](ClO4)2 along the c axis revealing a 3D str...
Figure 31: Size-dependent SCO properties in [Fe(pz)Pt(CN)4] (left), change of color upon spin state transition...
Figure 32: Schematic showing the epitaxial growth of polymer {Fe(pz)[Pt(CN)4]} and the spin transition propert...
Figure 33: Microcontact printing (μCP) of nanodots on Si-wafer of [Fe(ptz)6](BF4)2 after deposition of crystal...
Figure 34: (left) Projection of the two independent cations of [Fe(C6–trenH)]2+ with atom numbering scheme (15...
Figure 35: (a) χMT versus T for [Fe(C16-trenH)]Cl2·0.5H2O and variation of the distance d with temperature (T)...
Figure 36: Schematic illustration of the structure of compounds [Fe(Cn-tba)3]X2 adopting a columnar mesophase ...
Figure 37: Temperature dependence of the magnetic moment (M) at 1000 Oe and DSC profiles (inset; 5 °C/min) of ...
Figure 38: Porous structure of the SCO-PMOFs {Fe(pz)[M(II)(CN)4]} (left), representation of the host–guest int...
Figure 39: Porous structure of the guest-free SCO-PMOF’s {Fe(pz)[M(II)(CN)4]} (left), magnetic properties of t...
Figure 40: (left) The 3D porous structure of {Fe(pz)[Pt(CN)4]}·0.5(CS(NH2)2) (1) and {Fe(pz)[Pd(CN)4]}·1.5H2O·...
Figure 41: Top: The 3D porous structure of {Fe(dpe)[Pt(CN)4]}·phenazine in a direction close to [101] emphasiz...
Figure 42: View of the segregated stacking of [Ni(dmit)2]− and [Fe(sal2-trien)]+ in [Fe(qsal)2][Ni(dmit)2]3·CH3...
Figure 43: Thin films based on Fe(III) compounds coordinated to Terthienyl-substituted QsalH ligands [434] together...
Figure 44: Left: Temperature-dependent emission spectra for [Fe2(Hsaltrz)5(NCS)4]·4MeOH at λex = 350 nm over t...
Beilstein J. Org. Chem. 2013, 9, 278–302, doi:10.3762/bjoc.9.34
Graphical Abstract
Scheme 1: Variation of substrates for carbomagnesiation and carbozincation in this article.
Scheme 2: Copper-catalyzed arylmagnesiation and allylmagnesiation of alkynyl sulfone.
Scheme 3: Copper-catalyzed four-component reaction of alkynyl sulfoxide with alkylzinc reagent, diiodomethane...
Scheme 4: Rhodium-catalyzed reaction of aryl alkynyl ketones with arylzinc reagents.
Scheme 5: Allylmagnesiation of propargyl alcohol, which provides the anti-addition product.
Scheme 6: Negishi’s total synthesis of (Z)-γ-bisabolene by allylmagnesiation.
Scheme 7: Iron-catalyzed syn-carbomagnesiation of propargylic or homopropargylic alcohol.
Scheme 8: Mechanism of iron-catalyzed carbomagnesiation.
Scheme 9: Regio- and stereoselective manganese-catalyzed allylmagnesiation.
Scheme 10: Vinylation and alkylation of arylacetylene-bearing hydroxy group.
Scheme 11: Arylmagnesiation of (2-pyridyl)silyl-substituted alkynes.
Scheme 12: Synthesis of tamoxifen from 2g.
Scheme 13: Controlling regioselectivity of carbocupration by attaching directing groups.
Scheme 14: Rhodium-catalyzed carbozincation of ynamides.
Scheme 15: Synthesis of 4-pentenenitriles through carbometalation followed by aza-Claisen rearrangement.
Scheme 16: Uncatalyzed carbomagnesiation of cyclopropenes.
Scheme 17: Iron-catalyzed carbometalation of cyclopropenes.
Scheme 18: Enantioselective carbozincation of cyclopropenes.
Scheme 19: Copper-catalyzed facially selective carbomagnesiation.
Scheme 20: Arylmagnesiation of cyclopropenes.
Scheme 21: Enantioselective methylmagnesiation of cyclopropenes without catalyst.
Scheme 22: Copper-catalyzed carbozincation.
Scheme 23: Enantioselective ethylzincation of cyclopropenes.
Scheme 24: Nickel-catalyzed ring-opening aryl- and alkenylmagnesiation of a methylenecyclopropane.
Scheme 25: Reaction mechanism.
Scheme 26: Nickel-catalyzed carbomagnesiation of arylacetylene and dialkylacetylene.
Scheme 27: Nickel-catalyzed carbozincation of arylacetylenes and its application to the synthesis of tamoxifen....
Scheme 28: Bristol-Myers Squibb’s nickel-catalyzed phenylzincation.
Scheme 29: Iron/NHC-catalyzed arylmagnesiation of aryl(alkyl)acetylene.
Scheme 30: Iron/copper-cocatalyzed alkylmagnesiation of aryl(alkyl)acetylenes.
Scheme 31: Iron-catalyzed hydrometalation.
Scheme 32: Iron/copper-cocatalyzed arylmagnesiation of dialkylacetylenes.
Scheme 33: Chromium-catalyzed arylmagnesiation of alkynes.
Scheme 34: Cobalt-catalyzed arylzincation of alkynes.
Scheme 35: Cobalt-catalyzed formation of arylzinc reagents and subsequent arylzincation of alkynes.
Scheme 36: Cobalt-catalyzed benzylzincation of dialkylacetylene and aryl(alkyl)acetylenes.
Scheme 37: Synthesis of estrogen receptor antagonist.
Scheme 38: Cobalt-catalyzed allylzincation of aryl-substituted alkynes.
Scheme 39: Silver-catalyzed alkylmagnesiation of terminal alkyne.
Scheme 40: Proposed mechanism of silver-catalyzed alkylmagnesiation.
Scheme 41: Zirconium-catalyzed ethylzincation of terminal alkenes.
Scheme 42: Zirconium-catalyzed alkylmagnesiation.
Scheme 43: Titanium-catalyzed carbomagnesiation.
Scheme 44: Three-component coupling reaction.
Scheme 45: Iron-catalyzed arylzincation reaction of oxabicyclic alkenes.
Scheme 46: Reaction of allenyl ketones with organomagnesium reagent.
Scheme 47: Regio- and stereoselective reaction of a 2,3-allenoate.
Scheme 48: Three-component coupling reaction of 1,2-allenoate, organozinc reagent, and ketone.
Scheme 49: Proposed mechanism for a rhodium-catalyzed arylzincation of allenes.
Scheme 50: Synthesis of skipped polyenes by iterative arylzincation/allenylation reaction.
Scheme 51: Synthesis of 1,4-diorganomagnesium compound from 1,2-dienes.
Scheme 52: Synthesis of tricyclic compounds.
Scheme 53: Manganese-catalyzed allylmagnesiation of allenes.
Scheme 54: Copper-catalyzed alkylmagnesiation of 1,3-dienes and 1,3-enynes.
Scheme 55: Chromium-catalyzed methallylmagnesiation of 1,6-diynes.
Scheme 56: Chromium-catalyzed allylmagnesiation of 1,6-enynes.
Scheme 57: Proposed mechanism of the chromium-catalyzed methallylmagnesiation.
Beilstein J. Org. Chem. 2012, 8, 1788–1797, doi:10.3762/bjoc.8.204
Graphical Abstract
Figure 1: Flow cytometric uptake studies of carboxyfluorescein-labeled (sC18)2 in HEK-293 (human embryonic ki...
Figure 2: Top: Fluorescence microscopic images of unfixed HEK-293 cells after 30 min incubation with 1 µM CF-...
Figure 3: Cell viability of different cell lines after 24 h incubation with (sC18)2 at different concentratio...
Figure 4: Cell lysis of HEK-293 cells induced by (sC18)2 after 1 h incubation. Experiments were conducted in ...
Scheme 1: Synthesis of (sC18)2 bioconjugates (a) and chemical structures of the coupled anti-tumor agents (b)...
Figure 5: Chromatogram and ESI-MS of purified Cym2-GFL-(sC18)2. The gradient was 10→60% acetonitrile in water...
Figure 6: Circular dichroism spectra of the (sC18)2 conjugates. Spectra were acquired in 10 mM phosphate buff...
Figure 7: Cell viability of (a) HT-29 and (b) MCF-7 cells after 24 h incubation with the (sC18)2 conjugates a...
Figure 8: Brightfield microscopic images of unfixed HT-29 cells after 24 h incubation with the (sC18)2 conjug...
Figure 9: Cell lysis of (a) HT-29 and (b) MCF-7 cells induced by the (sC18)2 conjugates at different concentr...
Beilstein J. Org. Chem. 2012, 8, 787–803, doi:10.3762/bjoc.8.89
Graphical Abstract
Scheme 1: Synthesis of (4-{[(β-D-galactopyranosyl)oxy]methyl}furan-3-yl)methyl hydrogen sulfate (GSF, 5) and ...
Figure 1: Effects of increasing concentrations of (4-{[(β-D-galactopyranosyl)oxy]methyl}furan-3-yl)methyl hyd...
Figure 2: Inhibition of adhesion of WM-115 cells to fibrinogen (A), or to fibronectin (B) with increasing con...
Figure 3: Inhibition of adhesion of melanoma cells WM-115 to fibronectin-coated plastic by 5 mM (4-{[(β-D-gal...
Figure 4: In silico blind-docking (A, B) and molecular dynamic simulations (C) of (4-{[(β-D-galactopyranosyl)...
Figure 5: Intact cell monolayers of WM-115 cells in 12-well plates were wounded with a 100 µL pipette tip and...
Figure 6: A: Zymograms (color inverted) of serum-free conditioned medium of melanoma cells treated with (4-{[...
Figure 7: Adhesion of HBMEC-60 to extracellular matrix proteins. Prior to the adhesion experiments, HBMEC-60 ...
Figure 8: Effect of (4-{[(β-D-galactopyranosyl)oxy]methyl}furan-3-yl)methyl hydrogen sulfate (GSF) on transmi...
Figure 9: Influence of saccharide mimetics on endothelial networking (matrigel-assay) (A) and tube formation ...
Beilstein J. Org. Chem. 2012, 8, 606–612, doi:10.3762/bjoc.8.67
Graphical Abstract
Scheme 1: Concept for library generation by dipolar cycloaddition followed by boronate coupling.
Scheme 2: General formation of alkyl (R) and aryl (Ar) nitrile oxides.
Scheme 3: Formation of 4-(aldoxime)phenylboronic acid pinacol ester 5.
Beilstein J. Org. Chem. 2011, 7, 1722–1731, doi:10.3762/bjoc.7.202
Graphical Abstract
Figure 1: Dimethylaminophenylene end-capped sexithiophenes 1a and 1b, and dialkyl end-capped sexithiophenes 2a...
Scheme 1: The synthesis of functionalised oligothiophenes 1a,b and 2a,b. Reagents and conditions: a) NBS, CH3...
Figure 2: Solid-state voltammograms of 1b and 2b, as spin-coated films on ITO glass, versus Ag/AgCl reference...
Figure 3: Absorption spectra in solution (dichloromethane) and solid state.
Figure 4: UV–visible spectroelectrochemical measurements of 1b (left) and 2b (right) drop-cast onto ITO glass....
Figure 5: Absorption spectra for 1b and 2b, together with the absorption and emission profiles for the CdSe(Z...
Figure 6: The absorption spectra of increasing sexithiophene concentration with HDA capped CdSe(ZnS) quantum ...
Figure 7: Photoluminescence quenching experiments; the effect of increasing sexithiophene concentration with ...
Beilstein J. Org. Chem. 2011, 7, 1407–1411, doi:10.3762/bjoc.7.164
Graphical Abstract
Scheme 1: Proposed mechanism for the formation of 6.
Figure 1: Structure of alangiobussinine (7).
Scheme 2: Preparation of compounds 7 and 10. Reagents and conditions: i) LiOH (10 equiv), MeOH–H2O, rt, overn...
Beilstein J. Org. Chem. 2011, 7, 980–987, doi:10.3762/bjoc.7.110
Graphical Abstract
Scheme 1: Povarov oxidation access to substituted quinolines.
Scheme 2: Tetrahydroquinoline oxidation.
Scheme 3: Synthesis of the Povarov adducts and their oxidation products.
Figure 1: Optimization of the reaction conditions for the preparation of quinoline 18.
Scheme 4: Oxidation of lactam-fused tetrahydroquinolines 20,20'.